
Ex-Novartis exec joins Ipsen as President, Head of Specialty Care
pharmafile | February 8, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | appointment, ipsen
Harout Semerjian has joined French pharma firm Ipsen as President, Head of Specialty Care International Region & Global Franchises, the company has announced.
Semerjian was confirmed for the role at the same time the company announced that Dr Sotirios Stergiopoulos has also joined Ipsen as its Senior Vice President and Head of Global Medical Affairs.
Semerjian, who also takes on membership of the Executive Leadership Team at Ipsen, brings over 23 years of experience to the position. He joins the company from Novartis, a brand he served for 17 years, most recently as Senior Vice President and Global Launch Head of ribociclib. During his tenure, he has held responsibility for operations across the US, Canada, and EMEA.
Semerjian will report directly to Ipsen CEO David Meek, who commented on his appointment by saying, “I am delighted to welcome Harout Semerjian to Ipsen. Harout brings extensive leadership experience in oncology and has achieved success across a diverse range of markets including the U.S., Europe and the Middle East. He will be a tremendous asset to Ipsen, particularly as we accelerate our growth across markets and strengthen our focus on speciality care and oncology.”
Related Content

Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental …






